Grifols S.A (G0FB) - Total Liabilities
Based on the latest financial reports, Grifols S.A (G0FB) has total liabilities worth €12.11 Billion EUR (≈ $14.16 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore G0FB long-term investments to assets to see how much of total assets are deployed in long-term investments.
Grifols S.A - Total Liabilities Trend (2016–2025)
This chart illustrates how Grifols S.A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see G0FB current and non-current assets.
Grifols S.A Competitors by Total Liabilities
The table below lists competitors of Grifols S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Yanjing Brewery Co Ltd
SHE:000729
|
China | CN¥7.67 Billion |
|
Ningxia Orient Tantalum Industry Co Ltd
SHE:000962
|
China | CN¥814.10 Million |
|
Hanjaya Mandala Sampoerna Tbk PT
JK:HMSP
|
Indonesia | Rp21.48 Trillion |
|
Moelis & Co
NYSE:MC
|
USA | $766.60 Million |
|
Anhui Yingjia Distillery Co Ltd
SHG:603198
|
China | CN¥2.90 Billion |
|
ENTAIN PLC UNSP.ADR/1
F:6GI0
|
Germany | €7.91 Billion |
|
Marathon Digital Holdings Inc
NASDAQ:MARA
|
USA | $2.59 Billion |
|
Inficon Holding
SW:IFCN
|
Switzerland | CHF233.70 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Grifols S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Grifols S.A (G0FB) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Grifols S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Grifols S.A (2016–2025)
The table below shows the annual total liabilities of Grifols S.A from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €12.11 Billion ≈ $14.16 Billion |
-5.39% |
| 2024-12-31 | €12.80 Billion ≈ $14.96 Billion |
-5.05% |
| 2023-12-31 | €13.48 Billion ≈ $15.76 Billion |
+3.07% |
| 2022-12-31 | €13.08 Billion ≈ $15.29 Billion |
+17.95% |
| 2021-12-31 | €11.09 Billion ≈ $12.96 Billion |
+29.60% |
| 2020-12-31 | €8.55 Billion ≈ $10.00 Billion |
-1.63% |
| 2019-12-31 | €8.70 Billion ≈ $10.17 Billion |
+11.78% |
| 2018-12-31 | €7.78 Billion ≈ $9.10 Billion |
+6.78% |
| 2017-12-31 | €7.29 Billion ≈ $8.52 Billion |
+13.82% |
| 2016-12-31 | €6.40 Billion ≈ $7.48 Billion |
-- |
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more